Some of these ‘at-risk’ individuals will develop systemic autoimmunity and RA-related autoantibodies (stage C), such as anti-citrullinated protein antibody (ACPA) and/or rheumatoid factor (RF). Here, PRTN3 is linked to rheumatoid arthritis.